S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Fund/Baker Bros Advisors/Q4 2021

Baker Bros Advisors

Periodo: Q4 2021 Β· Depositato: 2022-02-14
Vedi su SEC EDGAR β†—
AUM
$20.55B
Valore totale del portafoglio
Posizioni
121
Titoli dichiarati
Prima Posizione
SGEN
35.3% $7.25B
Var. Trimestrali
+5 / -6
nuovi Β· usciti
⚠️Informativa sui Depositi 13F

I dati AUM mostrati sono calcolati sommando il valore di mercato dichiarato di tutte le posizioni nei depositi SEC 13F-HR β€” non rappresentano il patrimonio effettivo gestito dal fondo.

  • Escluse liquiditΓ , obbligazioni, private equity, posizioni corte e azioni estere non soggette all'obbligo di dichiarazione.
  • Per le opzioni PUT e CALL, il Valore dichiarato Γ¨ il valore nozionale delle azioni sottostanti β€” non il premio pagato. CiΓ² sovrastima significativamente il capitale effettivamente a rischio.
  • Il patrimonio reale del fondo Γ¨ tipicamente superiore e include strategie, strumenti e posizioni che non compaiono mai in un 13F.
  • I depositi 13F riguardano i gestori istituzionali con β‰₯$100M in titoli 13F. Le posizioni riflettono le partecipazioni a fine trimestre, divulgate entro 45 giorni dalla fine del periodo.

Dati provenienti da SEC EDGAR. Questo tracker Γ¨ a scopo puramente informativo e non costituisce consulenza finanziaria.

Partecipazioni in Portafoglio

Prime 30 posizioni

⚠️ Performance % calcolata dalla data di deposito ( 2022-02-14) si riferisce al titolo sottostante β€” non al P&L del derivato.
TickerEmittenteNozionalePortafoglio %Al DepositoOra (Fine Giornata)Dal DepositoAllocazione
SGENSeagen Inc.$7.25B35.27%β€”β€”
35.3%
ONCBeiGene, Ltd.$3.16B15.38%$270.93$297.65+9.9%
15.4%
INCYIncyte Corporation$2.47B12.01%$73.40$116.86+59.2%
12.0%
KODKodiak Sciences Inc.$1.24B6.06%$84.78$38.54-54.5%
6.1%
ACADACADIA Pharmaceuticals Inc.$978.2M4.76%$23.34$25.97+11.3%
4.8%
BMRNBioMarin Pharmaceutical Inc.$673.3M3.28%$88.35$58.99-33.2%
3.3%
ASNDAscendis Pharma A/S$611.0M2.97%$134.53$274.50+104.0%
3.0%
ARGXargenx SE$392.1M1.91%$350.19$939.68+168.3%
1.9%
MRTXMirati Therapeutics, Inc.$206.8M1.01%β€”β€”
1.0%
BCRXBioCryst Pharmaceuticals, Inc.$176.0M0.86%$13.85$9.84-28.9%
0.9%
KYMRKymera Therapeutics, Inc.$151.4M0.74%$63.49$113.51+78.8%
0.7%
NVTAQInvitae Corporation$150.8M0.73%β€”β€”
0.7%
ABCLAbCellera Biologics Inc.$149.4M0.73%$14.30$8.11-43.3%
0.7%
MDGLMadrigal Pharmaceuticals, Inc.$127.0M0.62%$84.74$528.10+523.2%
0.6%
PRLDPrelude Therapeutics Inc.$126.0M0.61%$12.45$4.91-60.6%
0.6%
LEGNLegend Biotech Corporation$116.0M0.56%$46.61$29.91-35.8%
0.6%
PACBPacific Biosciences of California, Inc.$111.4M0.54%$20.46$1.68-91.8%
0.5%
GBTGlobal Blood Therapeutics, Inc.$97.0M0.47%β€”β€”
0.5%
CERSCerus Corporation$93.4M0.45%$6.81$3.16-53.6%
0.5%
IGMSIGM Biosciences, Inc.$92.6M0.45%β€”β€”
0.5%
IMCRImmunocore Holdings plc$86.3M0.42%$34.24$32.50-5.1%
0.4%
TVTXTravere Therapeutics, Inc.$82.8M0.40%$31.04$56.92+83.4%
0.4%
TRDAEntrada Therapeutics, Inc.$80.5M0.39%$17.12$7.72-54.9%
0.4%
HRTXHeron Therapeutics, Inc.$74.2M0.36%$9.13$0.44-95.2%
0.4%
AMRNXXXXAmarin Corporation plc$71.3M0.35%β€”β€”
0.3%
NRIXNurix Therapeutics, Inc.$71.0M0.35%$28.95$23.97-17.2%
0.3%
TILInstil Bio, Inc.$66.6M0.32%$342.20$7.73-97.7%
0.3%
MRUSMerus N.V.$64.8M0.32%β€”β€”
0.3%
HZNPHorizon Therapeutics Public Ltd Co$64.6M0.31%β€”β€”
0.3%
IMTXImmatics N.V.$59.5M0.29%$13.44$9.95-26.0%
0.3%

AttivitΓ  Trimestre su Trimestre

Q4 2021 vs. Q3 2021

Nuove Posizioni (5)

TickerEmittenteNozionaleDal Deposito
TRDAEntrada Therapeutics, Inc.$80.5M-54.9%
TSVT2seventy bio, Inc.$21.4M
SRPTSarepta Therapeutics, Inc.$11.1M
FGENFibroGen, Inc.$8.2M
FHTXFoghorn Therapeutics Inc.$1.0M

Posizioni Chiuse (6)

TickerEmittenteNozionale
MIRMMirum Pharmaceuticals, Inc.$12.9M
AUPHAurinia Pharmaceuticals Inc.$11.5M
AMYTAmryt Pharma plc$6.2M
BioMarin Pharmaceutical Inc.$4.6M
XLRNAcceleron Pharma Inc.$3.9M
MREOMereo BioPharma Group plc$0.7M

Aumentate (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
AFMDAffimed N.V.$13.6M+1511.8%
CCXIChemoCentryx, Inc.$54.2M+441.6%
TCRRTCR2 Therapeutics Inc.$2.0M+326.8%
REPLReplimune Group, Inc.$11.5M+286.5%
RLMDRelmada Therapeutics, Inc.$5.9M+146.3%
KRYSKrystal Biotech, Inc.$24.8M+32.9%
TVTXTravere Therapeutics, Inc.$33.4M+30.9%+83.4%
TCDAQTricida, Inc.$7.5M+23.9%

Ridotte (8)

TickerEmittenteNozionaleVar. Azioni
ALBOAlbireo Pharma, Inc.$-10.4M-74.7%
Tricida, Inc.$-16.6M-63.3%
NVAXNovavax, Inc.$-15.7M-55.7%
FLGTFulgent Genetics, Inc.$-15.8M-49.8%
Apellis Pharmaceuticals, Inc.$-9.3M-32.1%
CRNXCrinetics Pharmaceuticals, Inc.$4.1M-10.1%
OPTEYOpthea Limited$-3.0M-5.5%
AMRNXXXXAmarin Corporation plc$-40.1M-3.1%
← Torna agli Hedge Fund